Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder

Alto Neuroscience (ANRO) PT Lowered to $10 at Baird

October 23, 2024 6:24 AM EDT

Baird analyst Brian Skorney lowered the price target on Alto Neuroscience (NYSE: ANRO) to $10.00 (from $32.00) while maintaining a Outperform rating.

The analyst comments "Lowering price target to $10 on ALTO-100 failure. Alto's first shot at its precision psychiatry approach failed to materialize... More